CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
2 research outputs found
Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial
Author
Buyze J.
Godinov Y.
+11Â more
Haughey S. Mulhern
Ito T.
Kambarov Y.
Luts A.
Messer T.
Nielsen R.
Reif A.
Rive B.
Usankova I.
von Holt C.
Yagcioglu A. E. Anil
Publication venue
Publication date
01/03/2023
Field of study
Get PDF
VBN
Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Tri
Author
Cubala W. J.
Godinov Y.
+9Â more
Ito T.
Mulhern-Haughey S.
Nielsen R. E.
Pirotte N.
Popova A.
Rive B.
Thilakarathne P.
Usankova I.
Young A. H.
Publication venue
Publication date
01/07/2023
Field of study
Get PDF
VBN